Moonwalk's novel platform technology provides a complete view of the epigenome in health and disease, with the most advanced AI prediction of epigenetic targets, and the broadest set of epigenetic engineering tools. The company was co-founded by Alex Aravanis, M.D., Ph.D., former CTO of Illumina, world-renowned scientist Feng Zhang, Ph.D. of the Broad Institute of MIT and Harvard, and a distinguished set of industry leaders and company builders. Moonwalk launched in January 2024 with $57 million raised led by Alpha Wave Ventures, and joined by other leading life sciences investors ARCH Venture Partners, Future Ventures, GV, Khosla Ventures and YK Bioventures.